Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Our RNAi play came from the understanding that personalization and the development of curated therapies are the future of ...

Significant advancements in gene silencing and gene editing offer new hope for treating rare disorders. Techniques like RNA ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

The new biotech is developing an antibody-oligo conjugate platform that uses "brain shuttles" to deliver drugs across the blood-brain barrier.

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA ...

Aerska has emerged from stealth and announced a $21m seed raise to advance its pipeline of medicines and grow its Irish and UK operations.

Alnylam Pharmaceuticals ALNY is Monday's IBD Stock Of The Day, with Alnylam stock flashing a buy signal as analysts expect ...